8-K ·Filed Apr 21, 2026

DGX

QUEST DIAGNOSTICS INC
BULLISH
Impact 8/10
Horizondays Processed5mo ago SEC0001022079-26-000040
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of revenue beat, EPS beat, and raised guidance suggests strong underlying momentum; monitor upcoming quarters for sustainability of organic volume growth and margin expansion.

DirectionBullish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
DGX ▲ +2.13% at T+60d
LONG call ✓ call won +2.13% · α vs SPY -4.77% · entry $205.04 → $209.41
Entry anchored
Apr 20, 03:59 PM ET
via exchange tick
T+1d
-0.51%
call -0.51% · α -1.53%
$204.00
settled 5mo ago
T+5d
-4.87%
call -4.87% · α -5.96%
$195.05
settled 5mo ago
T+20d
-7.41%
call -7.41% · α -12.33%
$189.84
settled 5mo ago
T+60d
+2.13%
call +2.13% · α -4.77%
$209.41
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Quest Diagnostics reported strong Q1 2026 results with revenue of $2.90 billion (up 9.2% YoY) and reported EPS of $2.24 (up 15.5% YoY), beating consensus. The company raised full-year 2026 EPS guidance, signaling confidence in sustained growth from organic volume expansion and operational execution.

Key Financial Metrics

EPS
$2.24
est $2.37 · -5.5%
Revenue
$2.9B
est $2.8B · +2.5% · +9.2% YoY
Rating
beat
Guidance
$11.78B-$11.90B
raised

Key Facts

  • Q1 2026 revenue was $2.90 billion, up 9.2% YoY with 9.0% organic growth
  • Reported diluted EPS was $2.24, up 15.5% YoY; adjusted EPS was $2.50, up 13.1% YoY
  • Company raised full-year 2026 adjusted EPS guidance to $10.63–$10.83 (from $10.50–$10.70)

Financial Impact

Revenue increased $250 million and EPS increased $0.30 YoY, with guidance raised above prior expectations

revenueepsoperating_income

Risk Factors

  • Guidance raise depends on continued execution of Project Nova and Co-Lab integrations
  • Exposure to reimbursement policy changes in clinical laboratory testing

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001022079-26-000040
Document: dgx-20260421.htm0001022079-26-000040
Document: 0001022079-26-000040-index-headers.html0001022079-26-000040
Document: 0001022079-26-000040-index.html0001022079-26-000040
Document: 0001022079-26-000040.txt0001022079-26-000040
8-K Data (Synthetic)0001022079-26-000040
9 reports for DGX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+5▲ +7.06%Sep 9, 2026
Filters
Rows
Reports for DGX — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Press Release
BULLISH ★ 6/10
$231.14 $247.45▲ +7.06%▲ +7.56%$233.27 (+0.92%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 3/10
$239.40 $235.02▼ −1.83%▼ −0.68%$233.27 (−2.56%)
Jul 23, 2026
10w ago
8-K
BULLISH ★ 7/10
$227.90 $234.30▲ +2.81%▲ +2.33%$233.27 (+2.36%)
May 8, 2026
20w ago
8-K
NEUTRAL ★ 2/10
$189.81 $189.84▲ +0.02%▲ +0.10%$233.27 (+22.90%)
Apr 21, 2026
23w ago
8-K
BULLISH ★ 8/10
$205.04 $195.05▼ −4.87%▼ −5.96%$233.27 (+13.77%)
Apr 16, 2026
24w ago
Court Ruling
NEUTRAL ★ 2/10
$191.46 $199.53▲ +4.21%▲ +3.25%$233.27 (+21.84%)
Mar 5, 2026
30w ago
Insider Cluster
BEARISH ★ 7/10
$203.09 $200.01▲ +1.52%▼ −0.72%$233.27 (−14.86%)
Mar 3, 2026
30w ago
Insider Cluster
NEUTRAL ★ 3/10
$207.46 $200.03▼ −3.58%▼ −3.10%$233.27 (+12.44%)
Mar 3, 2026
30w ago
Insider Cluster
NEUTRAL ★ 3/10
$207.46 $200.03▼ −3.58%▼ −3.10%$233.27 (+12.44%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (65h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access